Intec Pharma Ltd (NASDAQ:NTEC) has been given a consensus recommendation of “Buy” by the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $10.33.
A number of brokerages recently commented on NTEC. Zacks Investment Research upgraded Intec Pharma from a “sell” rating to a “hold” rating and set a $6.50 target price for the company in a report on Tuesday, May 7th. Oppenheimer cut Intec Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, July 22nd. LADENBURG THALM/SH SH lowered Intec Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, July 22nd. Maxim Group lowered Intec Pharma from a “buy” rating to a “hold” rating in a research report on Monday, July 22nd. Finally, ValuEngine raised Intec Pharma from a “hold” rating to a “buy” rating in a research report on Thursday.
Hedge funds have recently bought and sold shares of the business. Private Advisors LLC acquired a new stake in Intec Pharma in the 1st quarter valued at about $225,000. Menta Capital LLC acquired a new stake in shares of Intec Pharma during the 1st quarter worth about $248,000. BlackRock Inc. acquired a new stake in shares of Intec Pharma during the 4th quarter worth about $67,000. Knott David M raised its position in shares of Intec Pharma by 2.5% during the 1st quarter. Knott David M now owns 290,434 shares of the biotechnology company’s stock worth $2,129,000 after acquiring an additional 6,961 shares in the last quarter. Finally, Sigma Planning Corp acquired a new stake in shares of Intec Pharma during the 1st quarter worth about $183,000. 35.41% of the stock is currently owned by institutional investors.
Intec Pharma (NASDAQ:NTEC) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, analysts expect that Intec Pharma will post -1 earnings per share for the current fiscal year.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Story: Investing in Growth Stocks
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.